190711-50-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzenesulfonyl chloride, 4-[(dimethylamino)carbonyl]is used as a reagent for the synthesis of various pharmaceutical compounds. Its ability to provide the dimethylamino carbonyl group makes it a valuable component in the development of new drugs.
Used in Agricultural Chemical Industry:
Benzenesulfonyl chloride, 4-[(dimethylamino)carbonyl]is used as a reagent in the synthesis of agricultural chemicals. Its high reactivity and selectivity make it an important tool in the development of new agrochemicals.
Used in Dye Industry:
Benzenesulfonyl chloride, 4-[(dimethylamino)carbonyl]is used as a reagent in the synthesis of various dyes. Its versatility in organic reactions allows for the creation of a wide range of dyes with different properties.
Used in Specialty Chemicals Production:
Benzenesulfonyl chloride, 4-[(dimethylamino)carbonyl]is used as a building block in the production of specialty chemicals. Its unique properties and reactivity make it a valuable component in the development of advanced materials.

Upstream product

• 62-23-7 4-nitro-benzoic acid 
• 6331-71-1 4-amino-N,N-dimethylbenzamide 
• 7291-01-2 N,N-dimethyl-4-nitrobenzamide 
• 122-04-3 4-nitro-benzoyl chloride 
• 7516-60-1 4-chlorosulfonylbenzoyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 
• 636-78-2 4-sulphobenzoic acid 

Downstream Products

• 1580484-07-6 C₂₇H₂₄N₂O₅S 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

Kepner-Tregoe decision analysis as a tool to aid route selection. Part 2. Application to AZD7545, a PDK inhibitor

Kepner-Tregoe decision analysis was formally used as an aid to route selection, as outlined in the preceding paper. Over 40 paper routes were assessed for suitability for both immediate and longer term manufacture of AZD7545, a compound in the early stages of development. Eight routes were then investigated in full in the laboratory, and a further four in part, over a period of 3-4 months. From this exercise, the preferred long-term manufacturing route was identified before the first pilot scale manufacture had been completed. This route selection exercise worked well in this case where a large number of potential routes had to be considered using limited resources. It was also an effective means of bringing some long-term manufacturing issues to the fore at an early stage in development.

Remarkably Mild and Simple Preparations of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles

New and high yielding procedures to convert thioanisoles into versatile sulfonyl chloride derivatives were developed by strategically taking advantage of the Pummerer reaction.